Position in NVS
as of Jun 30, 2026
· filed Aug 6, 2026
Position Value
$1,567
+$40 QoQ
Shares Held
10
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#1,596
of 1,603 holders
Holding Since
Dec 2023
11 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Gold Investment Management Ltd. holds $14,557,675 across 12 Drug Manufacturers - General names. NVS ranks #11 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
19,891 | $5,051,717 | |
| 2 | LLY |
ELI LILLY & Co
|
2,391 | $2,867,837 | |
| 3 | MRK |
Merck & Co., Inc.
|
16,465 | $2,115,752 | |
| 4 | ABBV |
AbbVie Inc.
|
8,043 | $2,023,940 | |
| 5 | PFE |
Pfizer Inc
|
57,668 | $1,388,645 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
12,542 | $722,670 | |
| 7 | AMGN |
Amgen Inc
|
945 | $342,203 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
280 | $35,375 |
All Filings in NVS
Export CSV
11 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,567 | 10 | Shares | Sole | 2026-08-06 | |
| 2026-03-31 | $1,527 | 10 | Shares | Sole | 2026-04-22 | |
| 2025-12-31 | $1,378 | 10 | Shares | Sole | 2026-01-28 | |
| 2025-09-30 | $1,282 | 10 | Shares | Sole | 2025-10-29 | |
| 2025-06-30 | $1,210 | 10 | Shares | Sole | 2025-07-18 | |
| 2025-03-31 | $1,114 | 10 | Shares | Sole | 2025-04-24 | |
| 2024-12-31 | $973 | 10 | Shares | Sole | 2025-02-10 | |
| 2024-09-30 | $1,150 | 10 | Shares | Sole | 2024-10-31 | |
| 2024-06-30 | $1,064 | 10 | Shares | Sole | 2024-07-26 | |
| 2024-03-31 | $967 | 10 | Shares | Sole | 2024-05-03 | |
| 2023-12-31 | $1,009 | 10 | Shares | Sole | 2024-02-12 | |
| No filing history on record for this holder in this stock. | ||||||